Related Experiment Videos
Soluble class I antigen secretion by peripheral blood lymphocytes in multiple sclerosis
J C Alvarez-Cermeño1, J A Brieva, L M Villar
1Department of Neurology, Hospital Ramón y Cajal, Madrid, Spain.
European Neurology
|January 1, 1993
Summary
Soluble human leukocyte antigen (sHLA) secretion is reduced in multiple sclerosis (MS) patients, regardless of disease activity. This suggests systemic cell activation anomalies in MS, independent of relapse or progression.
Area of Science:
- Immunology
- Neuroimmunology
- Cellular Biology
Background:
- Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
- Understanding immune system dysregulation in MS is crucial for developing effective treatments.
- Soluble human leukocyte antigen (sHLA) class I molecules are involved in immune responses.
Purpose of the Study:
- To quantify soluble human leukocyte antigen (sHLA) class I antigen secretion by peripheral blood lymphocytes in multiple sclerosis (MS) patients.
- To investigate potential systemic anomalies in cell activation processes in MS.
- To determine if observed anomalies correlate with disease activity (stable, relapse, or progressive MS).
Main Methods:
- Quantification of sHLA secretion from peripheral blood lymphocytes of 26 MS patients and 29 healthy controls.
- Lymphocyte stimulation using phytohemagglutinin (PHA) and a monoclonal antibody anti-CD3.
- Assessment of lymphocyte proliferation and immunoglobulin secretion.
Main Results:
- Reduced sHLA secretion was observed in MS patients, irrespective of disease activity (stable, relapse, or progressive).
- sHLA secretion was normalized upon stimulation with anti-CD3, but remained reduced with phytohemagglutinin.
- Lymphocyte proliferation and immunoglobulin secretion were comparable between MS patients and healthy controls.
Conclusions:
- MS patients exhibit systemic anomalies in the cell activation process, specifically affecting sHLA secretion.
- These alterations appear to be independent of MS disease activity.
- Further research is needed to determine if these findings are specific to MS or indicative of broader inflammatory central nervous system (CNS) disease processes.